高级搜索

免疫检查点抑制剂在肝细胞癌治疗中的研究进展

曹佳丽, 熊枝繁, 靳泽, 孟亚君, 黄雨梅, 朱梦培, 汪朦朦

曹佳丽, 熊枝繁, 靳泽, 孟亚君, 黄雨梅, 朱梦培, 汪朦朦. 免疫检查点抑制剂在肝细胞癌治疗中的研究进展[J]. 肿瘤防治研究, 2023, 50(5): 525-530. DOI: 10.3971/j.issn.1000-8578.2023.22.1325
引用本文: 曹佳丽, 熊枝繁, 靳泽, 孟亚君, 黄雨梅, 朱梦培, 汪朦朦. 免疫检查点抑制剂在肝细胞癌治疗中的研究进展[J]. 肿瘤防治研究, 2023, 50(5): 525-530. DOI: 10.3971/j.issn.1000-8578.2023.22.1325
CAO Jiali, XIONG Zhifan, JIN Ze, MENG Yajun, HUANG Yumei, ZHU Mengpei, WANG Mengmeng. Research Progress on Immune Checkpoint Inhibitors in Treatment of Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2023, 50(5): 525-530. DOI: 10.3971/j.issn.1000-8578.2023.22.1325
Citation: CAO Jiali, XIONG Zhifan, JIN Ze, MENG Yajun, HUANG Yumei, ZHU Mengpei, WANG Mengmeng. Research Progress on Immune Checkpoint Inhibitors in Treatment of Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2023, 50(5): 525-530. DOI: 10.3971/j.issn.1000-8578.2023.22.1325

免疫检查点抑制剂在肝细胞癌治疗中的研究进展

基金项目: 

国家科技部重点研发计划 2018YFC2002000

详细信息
    作者简介:

    曹佳丽(1998-),女,硕士在读,住院医师,主要从事肝细胞癌诊治的基础和临床研究,ORCID: 0009-0000-2806-0265

    通讯作者:

    熊枝繁(1962-),男,博士,教授,主要从事消化系统疾病的综合治疗研究,E-mail: xiongzhifan@126.com,ORCID: 0000-0001-7190-8073

  • 中图分类号: R730.51

Research Progress on Immune Checkpoint Inhibitors in Treatment of Hepatocellular Carcinoma

Funding: 

National Key Research and Development Program of China 2018YFC2002000

More Information
  • 摘要:

    肝细胞癌(HCC)是癌症相关死亡的最常见原因之一,大多数HCC患者在癌症晚期被诊断出来。2017年以前,治疗晚期HCC的药物主要是酪氨酸激酶抑制剂,随着免疫检查点抑制剂(ICIs)的出现,免疫治疗逐渐给此类患者带来新希望。目前,ICIs与其他全身或局部治疗的联合方案已成为治疗晚期HCC最有潜力的策略,其中一些药物已进行大规模临床试验。晚期HCC免疫治疗的主要挑战包括预测性生物标志物的探索、免疫相关不良事件(irAEs)的管理以及发掘更有效的联合方案等。本文旨在对肝细胞癌ICIs单药或联合用药以及其他免疫治疗的最新进展进行综述,并讨论目前研究与临床应用的限制和未来发展方向。

     

    Abstract:

    Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related death, and most patients with HCC are diagnosed at an advanced stage. Before 2017, tyrosine kinase inhibitors were the main drugs for the treatment of advanced hepatocellular carcinoma. With the emergence of immune checkpoint inhibitors (ICIs), immunotherapy has gradually brought new hope to such patients. At present, the combination of ICIs and other systemic or local treatments has become a potential strategy for the treatment of advanced hepatocellular carcinoma, and some of these combinations have been included in large-scale clinical trials. The main challenges of immunotherapy for advanced hepatocellular carcinoma include the exploration of predictive biomarkers, management of immune-related adverse events, and exploration of effective combination regimens. This article provides the latest research progress on the single or combined use of ICIs and other immunotherapy for hepatocellular carcinoma and discusses the limitations of current research and clinical application and the future development direction.

     

  • 肝癌是全球常见的恶性肿瘤之一,病理类型有肝细胞癌(hepatocellular carcinoma, HCC)、肝内胆管细胞癌、混合癌,其中肝细胞癌占85%~90%[1]。根据2020年癌症全球人数统计,肝癌是全球第三大癌症死亡原因,死亡人数占癌症总死亡人数的8.3%,是中国癌症死亡人数的第2名[2]。我国肝癌5年生存率不足15%[3]。甲胎蛋白(alpha-fetoprotein, AFP)是筛查HCC的常用指标,术后AFP升高常提示HCC复发,但约30%的患者AFP没有升高或不表达,延误治疗最佳时机[4]。临床上需要联合有效的指标协助判断患者预后,提高生存质量。

    血清乳酸脱氢酶/白蛋白比值(lactate dehydrogenase to albumin ratio, LAR)是判断恶性肿瘤预后的血清学检测指标之一。在多种癌症的研究中显示,血清乳酸脱氢酶(LDH)水平是肿瘤缺氧、新生血管生成和预后不良的间接标志[5]。术前低蛋白血症是营养不良的指标,与胃癌和肝癌等患者的总体存活率低和复发率高有关[5-6]。LAR在胃癌和鼻咽癌等癌症中的不良预后作用已被验证,而在HCC中研究较少。本研究回顾性分析106例HCC患者临床资料,评价患者术前外周血LAR与预后的关系,并将LAR联合AFP来评估HCC患者预后的价值,以期为HCC的临床判断提供一定的参考。

    回顾性分析2015年1月—2019年12月在兰州大学第一医院普外科行根治性手术的106例HCC患者的临床资料,其中男81例(76.4%),女25例(23.6%);年龄26~78(54.5±10.1)岁。临床分期按照2018年修改的AJCC第8版分期系统。纳入标准:(1)18~80岁;(2)术中肿瘤根治性切除;(3)术后病理证实为HCC;(4)无严重的心、肺、脑、肾严重功能障碍及血液系统疾病;(5)患者临床及随访资料完整。排除标准:(1)不可切除或非根治性切除的肝癌;(2)术后病理证实非HCC;(3)既往有其他恶性肿瘤病史者;(4)拒绝签署知情同意书及随访过程中失访者。本研究通过本院伦理委员会审批(批准号:LDYYLL2021-348)。

    收集患者的基本信息:性别、年龄、体重指数;术前1周内的血常规检查:肝炎病毒抗原、白蛋白(ALB)、LDH、AFP;影像学检查;疾病信息:肿瘤T分期、N分期、临床分期、术后有无介入手术治疗等。

    采用住院或门诊就诊、电话等方式进行随访,每3月随访一次,末次随访时间为2021年5月。总生存期(overall survival, OS)是从患者术后第1日开始至末次随访或死亡的时间;无病生存期(disease-free survival, DFS)是患者手术后第1日至疾病复发或(因任何原因)死亡之间的时间[7]。随访时间为0~77月,中位随访时间为28月。106例随访病例复发75例(70.8%),死亡30例(28.3%),1例未复发。

    采用SPSS26.0软件进行统计学分析。根据中位数以LAR为4.58进行分层(LAR≥4.58和LAR < 4.58)。计数资料用例数和百分比表示,两组间比较采用χ2或Fisher精确检验,等级变量采用秩和检验。使用Kaplan-Meier绘制生存曲线并采用Log rank检验。利用Cox风险回归模型进行单多因素回归分析,判断影响HCC患者预后的危险因素;对LAR和AFP联合分组进行检验,并绘制Kaplan-Meier生存曲线。P < 0.05为差异有统计学意义。

    106例患者中,1年的DFS为49.1%,3年的DFS为9.4%,1年的OS为81.1%,3年的OS为22.6%。根据既往研究结果,取AFP截断值为400 μg/L,以LAR=4.58为阈值分层,单因素分析显示两组间T分期和临床分期比较差异有统计学意义(均P < 0.05),见表 1

    表  1  HCC患者的临床资料与LAR相关性分析(n(%))
    Table  1  Correlation between clinical data and LAR of HCC patients (n(%))
    下载: 导出CSV 
    | 显示表格

    高LAR组(LAR≥4.58, n=53),低LAR组(LAR < 4.58, n=53);高AFP组(AFP≥400 μg/L, n=24),低AFP组(AFP < 400 μg/L, n=82)。Log rank检验单因素分析显示,高LAR组和高AFP组的DFS和OS显著短于低LAR组和低AFP组,差异有统计学意义(P < 0.05),Kaplan-Meier生存曲线见图 1

    图  1  不同的LAR和AFP值与HCC患者术后无病生存期(A, C)和总生存期(B, D)的关系
    Figure  1  Relation between different LAR, AFP values and postoperative DFS(A, C), OS(B, D) of HCC patients

    按照中位数患者被分为高LAR组(LAR≥4.58, n=53)和低LAR组(LAR < 4.58, n=53)。根据既往文献对T分期进行分类(T1~T2/T3~T4),将HCC患者性别、年龄、BMI、肝炎病毒抗原、LAR、AFP、T分期、N分期和术后介入治疗等因素纳入Cox单因素回归分析,结果表明LAR、AFP、T分期与DFS相关(P < 0.05),LAR、AFP、T分期、术后介入治疗与OS相关(P < 0.05)。将单因素分析中有临床意义的变量纳入多因素回归分析,结果显示高LAR、高AFP和T3~T4期是HCC患者DFS和OS的独立危险因素(P < 0.05),术后行介入手术治疗可延长HCC患者的OS,见表 2

    表  2  HCC患者DFS和OS的Cox单多因素回归分析
    Table  2  Cox univariate and multivariate regression analyses of DFS and OS in HCC patients
    下载: 导出CSV 
    | 显示表格

    结果显示高LAR且高AFP组(LAR≥4.58且AFP≥400 μg/L, n=12)的DFS和OS最短,低LAR且低AFP组(LAR < 4.58且AFP < 400 μg/L, n=41)的DFS和OS最长(P < 0.05),见图 2

    图  2  血清LAR及AFP水平与肝细胞患者术后无病生存期(A)和总生存期(B)的关系
    Figure  2  Relation between serum LAR, AFP levels and postoperative DFS(A), OS(B) of HCC patients

    肝癌是我国第四大常见恶性肿瘤[8],据2018年世界卫生组织(WHO)统计,我国肝癌人数占全球肝癌病例总数的46.7%[9]。肝癌主要的危险因素有慢性乙型病毒性肝炎、慢性丙型病毒性肝炎、酗酒、代谢性肝病等。目前AFP作为临床最常用的血液学检测方法对HCC进行筛查和预后监测,但其敏感度较低,为25%~65%[1]。因此需联合简单可行的血液学检测方法对HCC预后进行判断,早期实施干预措施,改善HCC预后。

    高LDH和低ALB水平提示恶性肿瘤的不良预后,LAR将LDH与ALB结合可在肿瘤血管生成、细胞存活和机体营养状况等方面综合判断肿瘤预后,准确性较单个指标更高,其不良预后作用在结直肠癌、食管癌等多种肿瘤中得到验证[10-11]。Gan等[6]对1 041例原发性肝癌患者进行分析,发现LAR是原发性肝癌患者OS和无进展生存期(progression-free survival, PFS)的准确预测因子。本研究发现术前LAR与肿瘤的T分期和临床分期相关,与以往研究结果一致,高LAR是HCC的独立不良预后因素,高LAR水平的HCC患者,术后复发风险比低LAR组高约1.606倍。

    LDH是一种参与无氧糖酵解的代谢酶[11],高LDH与肿瘤血管生成、细胞存活和肿瘤形成相关[12],是胃癌、胰腺癌等恶性肿瘤的不良预后因素[10-11, 13]。Wu等[14]研究显示LDH是原发性肝癌患者OS和PFS的独立预后因素。高LDH提示不良预后的可能原因有:(1)肿瘤细胞增殖活跃、肿瘤微环境氧耗增加[15]、缺氧诱导因子-1(HIF-1)的异常激活可上调肿瘤细胞中的LDH-A,确保肿瘤细胞在低氧条件下进行糖酵解代谢并且减少对氧气的需求[16];(2)PI3K/Akt/mTOR通路是肿瘤中最常被激活的信号通路之一,可通过调节LDH促进肿瘤细胞增殖、生长[17];(3)异常激活的热休克蛋白通过其转录调节因子热休克因子(HSF-1),调节葡萄糖代谢和增加乳酸脱氢酶(LDH-A)的表达[18],促进肿瘤细胞的增值、侵袭和转移。ALB作为肝脏合成的糖蛋白,是判断肝功能是否损伤的早期重要指标[19]。Fox等[20]通过分析2 918例患者的临床资料发现术前低蛋白血症为原发性肝癌不良预后的重要因素。术前白蛋白水平较低的原因可能有:肝功能障碍引起白蛋白合成、分泌较少;肿瘤相关的炎性反应引起蛋白分解加速[5]。LAR为LDH和ALB值之比,LAR升高不仅可以反应LDH升高,也可反应ALB降低。本研究通过对106例患者分析发现高LAR组患者的DFS和OS短于低LAR组患者,且差异有统计学意义(P < 0.05),与上述研究结果基本一致。

    本研究发现,LAR和AFP均与HCC的不良预后密切相关,LAR和AFP均升高的组预后最差,对HCC患者术后DFS和OS的判断有统计学意义。本研究为单中心、小样本的回顾性研究,存在一定的局限性,未来需进行多中心、大样本的前瞻性研究,进一步了解影响肝癌预后的危险因素,提高对肝癌预后判断的准确性,及时干预治疗,延长DFS和OS,提高患者生存质量。

    Competing interests: The authors declare that they have no competing interests.
    利益冲突声明:
    所有作者均声明不存在利益冲突。
    作者贡献:
    曹佳丽:文章构思、资料收集与解读、文章撰写与修改
    熊枝繁:文章选题、设计及审校
    靳泽、孟亚君:资料收集及解读
    黄雨梅、朱梦培、汪朦朦:文章修改
  • [1]

    Lin L, Li Z, Yan L, et al. Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990-2019[J]. J Hematol Oncol, 2021, 14(1): 197. doi: 10.1186/s13045-021-01213-z

    [2]

    Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4): 378-390. doi: 10.1056/NEJMoa0708857

    [3]

    Cariani E, Missale G. Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications[J]. Liver Int, 2019, 39(9): 1608-1621. doi: 10.1111/liv.14192

    [4]

    El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. doi: 10.1016/S0140-6736(17)31046-2

    [5]

    Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial[J]. Lancet Oncol, 2022, 23(1): 77-90. doi: 10.1016/S1470-2045(21)00604-5

    [6]

    Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase Ⅲ Trial[J]. J Clin Oncol, 2020, 38(3): 193-202. doi: 10.1200/JCO.19.01307

    [7]

    Kudo M, Finn RS, Edeline J, et al. Updated efficacy and safety of KEYNOTE-224: a phaseⅡ study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib[J]. Eur J Cancer, 2022, 167: 1-12. doi: 10.1016/j.ejca.2022.02.009

    [8]

    Ren Z, Qin S, Meng Z, et al. A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression[J]. Liver Cancer, 2021, 10(5): 500-509. doi: 10.1159/000516470

    [9]

    Kelley RK, Sangro B, Harris W, et al. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a PhaseⅠ/Ⅱ Study[J]. J Clin Oncol, 2021, 39(27): 2991-3001. doi: 10.1200/JCO.20.03555

    [10]

    Yau T, Kang YK, Kim TY, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial[J]. JAMA Oncol, 2020, 6(11): e204564. doi: 10.1001/jamaoncol.2020.4564

    [11]

    Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905. doi: 10.1056/NEJMoa1915745

    [12]

    Cheon J, Yoo C, Hong JY, et al. Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma[J]. Liver Int, 2022, 42(3): 674-681. doi: 10.1111/liv.15102

    [13]

    Di Federico A, Rizzo A, Carloni R, et al. Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials[J]. Expert Opin Investig Drugs, 2022, 31(4): 361-369. doi: 10.1080/13543784.2022.2009455

    [14]

    Ren ZG, Xu JM, Bai YX, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7): 977-990. doi: 10.1016/S1470-2045(21)00252-7

    [15]

    Finn RS, Ikeda M, Zhu AX, et al. PhaseⅠb Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma[J]. J Clin Oncol, 2020, 38(26): 2960-2970. doi: 10.1200/JCO.20.00808

    [16]

    Kelley RK, Oliver JW, Hazra S, et al. Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase Ⅲstudy design[J]. Future Oncol, 2020, 16(21): 1525-1536. doi: 10.2217/fon-2020-0283

    [17]

    Yau T, Zagonel V, Santoro A, et al. Nivolumab (NIVO) plus ipilimumab (IPI) plus cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040[J]. J Clin Oncol, 2020, 38(4): 2. http://www.researchgate.net/publication/339038671_Nivolumab_NIVO_ipilimumab_IPI_cabozantinib_CABO_combination_therapy_in_patients_pts_with_advanced_hepatocellular_carcinoma_aHCC_Results_from_CheckMate_040

    [18]

    Mei K, Qin S, Chen Z, et al. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phaseⅠb/Ⅱ trial[J]. J Immunother Cancer, 2021, 9(3): e002191. doi: 10.1136/jitc-2020-002191

    [19]

    Liu Q, You N, Li J, et al. Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis[J]. Front Oncol, 2021, 11: 694409. doi: 10.3389/fonc.2021.694409

    [20]

    Mizukoshi E, Yamashita T, Arai K, et al. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma[J]. Hepatology, 2013, 57(4): 1448-1457. doi: 10.1002/hep.26153

    [21]

    Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol, 2017, 66(3): 545-551. doi: 10.1016/j.jhep.2016.10.029

    [22]

    Wang PF, Chen Y, Song SY, et al. Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis[J]. Front Pharmacol, 2017, 8: 730. doi: 10.3389/fphar.2017.00730

    [23]

    Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis[J]. BMC Med, 2015, 13: 211. doi: 10.1186/s12916-015-0455-8

    [24]

    Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma[J]. N Engl J Med, 2015, 373(13): 1270-1271. doi: 10.1056/NEJMc1509660

    [25]

    Terrault NA, Lok ASF, Mcmahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. doi: 10.1002/hep.29800

    [26]

    Xu S, Lai R, Zhao Q, et al. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors[J]. Front Immunol, 2021, 12: 794099. doi: 10.3389/fimmu.2021.794099

    [27]

    Lee PC, Chao Y, Chen MH, et al. Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma[J]. Cancers (Basel), 2020, 12(1): 182. doi: 10.3390/cancers12010182

    [28]

    Oh S, Park Y, Lee HJ, et al. A Disintegrin and Metalloproteinase 9 (ADAM9) in Advanced Hepatocellular Carcinoma and Their Role as a Biomarker During Hepatocellular Carcinoma Immunotherapy[J]. Cancers (Basel), 2020, 12(3): 745. doi: 10.3390/cancers12030745

    [29]

    Tanaka Y, Tateishi R, Koike K. Proteoglycans Are Attractive Biomarkers and Therapeutic Targets in Hepatocellular Carcinoma[J]. Int J Mol Sci, 2018, 19(10): 3070. doi: 10.3390/ijms19103070

    [30]

    Metwaly HA, El-Gayar AM, El-Shishtawy MM. Inhibition of the signaling pathway of syndecan-1 by synstatin: A promising anti-integrin inhibitor of angiogenesis and proliferation in HCC in rats[J]. Arch Biochem Biophys, 2018, 652: 50-58. doi: 10.1016/j.abb.2018.06.007

    [31]

    Zheng Y, Wang T, Tu X, et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma[J]. J Immunother Cancer, 2019, 7(1): 193. doi: 10.1186/s40425-019-0650-9

    [32]

    Cerrito L, Ainora ME, Mosoni C, et al. Prognostic Role of Molecular and Imaging Biomarkers for Predicting Advanced Hepatocellular Carcinoma Treatment Efficacy[J]. Cancers (Basel), 2022, 14(19): 4647. doi: 10.3390/cancers14194647

    [33]

    Patel SA, Minn AJ. Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies[J]. Immunity, 2018, 48(3): 417-433. doi: 10.1016/j.immuni.2018.03.007

  • 期刊类型引用(9)

    1. 赵建红,岑红兵,杨志勇,陈峰. FEN1调节肝细胞癌发生和预后的临床意义. 局解手术学杂志. 2024(04): 349-354 . 百度学术
    2. 田颖,王根杰,胡青竹. 乳酸脱氢酶/白蛋白对多发性骨髓瘤患者硼替佐米化疗耐药的影响. 河南医学研究. 2024(10): 1806-1809 . 百度学术
    3. 宋丽丽,马平,管玉洁,黄闪,刘炜. 急性B淋巴细胞白血病儿童乳酸脱氢酶、前白蛋白及二者比值与化疗早期疗效的相关性. 现代临床医学. 2024(05): 326-329 . 百度学术
    4. 张郴华,邓英. 血清寡糖链与甲胎蛋白联合检测在肝细胞癌诊断及其预后评估中的应用价值分析. 大医生. 2023(09): 122-125 . 百度学术
    5. 王珊,张立婷,高晓琴,周丹. 术前抗病毒治疗对HBV-DNA阴性肝细胞癌患者术后病毒再激活及肝功能的影响. 婚育与健康. 2023(06): 37-39 . 百度学术
    6. 黎灵锋,刘桂荣,谢燕芳,巫宗由. 血清谷胱甘肽还原酶在HBV相关性肝病中的应用研究. 标记免疫分析与临床. 2023(02): 304-308 . 百度学术
    7. 汪祥兵,朱正春. LAR对信迪利单抗联合贝伐珠单抗治疗中晚期肝细胞癌患者预后的价值. 安徽医学. 2023(09): 1095-1100 . 百度学术
    8. 汪敏行,阴鲁鑫,石叶,陈洪福,褚夫政,高文昌. 脑胶质瘤患者血清MBP、LAR、AGR与术后脑损伤和预后的关系研究. 现代生物医学进展. 2023(20): 3974-3978 . 百度学术
    9. 仲伟明,吴银亚,段后张,刘雷,蔡景治. 血清ESM-1水平预测肝细胞癌患者射频消融术后早期复发的临床意义. 临床肿瘤学杂志. 2023(10): 907-912 . 百度学术

    其他类型引用(3)

计量
  • 文章访问数:  1656
  • HTML全文浏览量:  414
  • PDF下载量:  1256
  • 被引次数: 12
出版历程
  • 收稿日期:  2022-11-08
  • 修回日期:  2023-02-15
  • 网络出版日期:  2024-01-12
  • 刊出日期:  2023-05-24

目录

/

返回文章
返回
x 关闭 永久关闭